GXDX provides diagnostic services to community based oncologists and hematologist treating blood, bone marrow and other cancers. This business has been amazing for this company as the fundamentals have many mutual funds wanting to load up on this stock. That is why we have seen ownership grow from 27 funds last quarter to 42 funds in the most recent quarter.

This sort of accumulation with a management owning 46% of the shares outstanding is a severe confirmation of future price gains.

GXDSX has had some incredible recent quarterly EPS growth of 200%, 388%, 540%, 999% and 325% the past five quarters. On top of that current growth we have EPS estimates for 2008 and 2009 for YOY growth of 18% and 4% respectively.

Along with the incredible earings, the sales growth are doubly impressive with growth o f417%, 340%, 264%, 166%, 165%, 134%, 137%, and 109% the past eight quarters. This kind of …

Vision-Sciences, Inc is engaged in the development and manufacturing of advanced, video-based endoscopy equipment. The company’s digital endoscope lines are set apart from the competition in that they come with a built-in light source, unlike traditional scopes which must be fitted with a separate camera head and light cable. Perhaps the most significant product offered by Vision-Sciences is its patented Slide-On EndoSheath, a disposable endoscope cover which eliminates the patient’s chance of infection.

The company has had several breakthroughs in the way of product approvals by various organizations in recent weeks. Health Canada gave Vision-Sciences’ scopes the go-ahead, clearing the way for distribution throughout Canada and Europe. Underwriter’s Laboratories also provided its stamp of approval, enabling Vision-Science to affix the “CE” mark to its product. CEO Ron Hadani says his company’s products have created “overwhelming interest” in the medical community, which can be appeased, now that the proper certifications have